KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Operating Leases (2018 - 2025)

BioNTech SE's Operating Leases history spans 8 years, with the latest figure at $242.0 million for Q3 2025.

  • On a quarterly basis, Operating Leases changed N/A to $242.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $242.0 million, a N/A change, with the full-year FY2024 number at $271.6 million, up 16.5% from a year prior.
  • Operating Leases hit $242.0 million in Q3 2025 for BioNTech SE, down from $260.5 million in the prior quarter.
  • Over the last five years, Operating Leases for BNTX hit a ceiling of $274.4 million in Q3 2022 and a floor of $117.7 million in Q2 2021.
  • Historically, Operating Leases has averaged $225.4 million across 5 years, with a median of $242.0 million in 2025.
  • Biggest five-year swings in Operating Leases: soared 115.3% in 2022 and later increased 2.12% in 2025.
  • Tracing BNTX's Operating Leases over 5 years: stood at $207.7 million in 2021, then rose by 3.18% to $214.4 million in 2022, then increased by 8.77% to $233.2 million in 2023, then increased by 16.5% to $271.6 million in 2024, then fell by 10.91% to $242.0 million in 2025.
  • Business Quant data shows Operating Leases for BNTX at $242.0 million in Q3 2025, $260.5 million in Q2 2025, and $259.6 million in Q1 2025.